Table: Attractive Targets

Product pipelines at these companies could attract suitors or partners:

CV THERAPEUTICS

Has promising drugs in development, including ranolazine, for angina, which could launch in 2003 and top $500 million in sales.

GILEAD SCIENCES

Its HIV drug was just approved, and a Hepatitis B treatment is in development. Combined sales of the two could top $1 billion.

TRANSKARYOTIC THERAPIES

Awaiting Food & Drug Administration approval for Replagal, a treatment for a rare metabolic disease. This could blossom into a $300 million drug.

TRIMERIS

Its 50-50 partnership with Hoffmann-La Roche is developing "fusion inhibitor" drugs for HIV. The first could exceed $400 million in revenues.

Data: Mehta Partners, Lehman Brothers & SG Cowen

    Before it's here, it's on the Bloomberg Terminal.
    LEARN MORE